Adc Therapeutics Sa (ADCT) Stock Price, Quote & News

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 21 653 02 00

Website: www.adctherapeutics.com

Address:

BiopOle, Route de la Corniche 3B, Epalinges, Switzerland

RadioIsotope25 Nov. 12 at 11:22 PM

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 $ADCT $PYXS https://finance.yahoo.com/news/radiopharm-theranostics-starts-enrollment-third-133000810.html

0 · Reply

Rox22 Nov. 10 at 5:01 PM

$ADCT Lotus 7 (bispecific combo) by end of year. Lotus 5 (Rix combo) H1 2026 Timeline is below. See the link for the whole presentation and the picture for the timeline. Good earnings call. I think their projection for their revenue was very conservative. During the Q&A he went through some math on potential markets moving into second line therapy. https://s24.q4cdn.com/575174480/files/doc_presentations/2025/Nov/09/ADCT-3Q-2025-EarningsDeck-110725.pdf

0 · Reply

hechicero1131 Nov. 10 at 4:13 PM

$ADCT did anyone listen to the earnings call? Wondering when they are expected to release data readout. They have three investor conferences this month, expect to see something soon

0 · Reply

hechicero1131 Nov. 7 at 4:41 PM

$ADCT Up 5% yesterday, down 10% today - on intermediate volume. They are hiring like crazy and an earnings report on Monday. Down 10% makes no sense

0 · Reply

SamHot Nov. 6 at 10:39 PM

$ADCT

0 · Reply

Rony4AM Nov. 6 at 10:27 PM

0 · Reply

christopher18 Nov. 5 at 3:41 PM

$ADCT Earnings predictions?

0 · Reply

hechicero1131 Nov. 3 at 5:35 PM

$ADCT any insights from today’s fireside chat re. Data findings?

0 · Reply

Trhays0620 Oct. 31 at 1:31 AM

$ADCT showing a 94% loss on my position on Schwab. Anyone else have weirdness going on?

0 · Reply

scalpemfast Oct. 29 at 4:20 PM

$ADCT ,$CRWV ,$AMZN ,$ETN , all pressing up , looking strong .

0 · Reply

ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 4 days ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 3, 2025, 7:15 AM EST - 11 days ago

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

Oct 27, 2025, 7:15 AM EDT - 18 days ago

ADC Therapeutics to Present at November Investor Conferences

Oct 13, 2025, 7:30 AM EDT - 4 weeks ago

ADC Therapeutics Announces $60 Million Private Placement

Oct 1, 2025, 4:05 PM EDT - 6 weeks ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Aug 27, 2025, 7:15 AM EDT - 2 months ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 12, 2025, 11:27 AM EDT - 3 months ago

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:30 AM EDT - 3 months ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 5, 2025, 4:05 PM EDT - 3 months ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Jul 1, 2025, 4:05 PM EDT - 4 months ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jun 16, 2025, 7:15 AM EDT - 5 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 12, 2025, 6:45 AM EDT - 5 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:30 AM EDT - 5 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

May 15, 2025, 7:15 AM EDT - 6 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 12:36 PM EDT - 6 months ago

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

May 14, 2025, 8:00 AM EDT - 6 months ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 7:45 AM EDT - 6 months ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 8, 2025, 7:15 AM EDT - 6 months ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

Apr 28, 2025, 7:00 AM EDT - 7 months ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 1, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 11:17 AM EDT - 8 months ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 8 months ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 25, 2025, 5:30 PM EDT - 8 months ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 24, 2025, 11:08 PM EDT - 8 months ago

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

Mar 20, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Jan 30, 2025, 7:15 AM EST - 10 months ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 30, 2024, 4:30 PM EST - 11 months ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 12, 2024, 2:03 PM EST - 1 year ago

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

$ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 11, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

$ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma$

Dec 9, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 6, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Nov 9, 2024, 11:01 AM EST - 1 year ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 1:14 PM EST - 1 year ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 7, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 5, 2024, 9:47 AM EST - 1 year ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Oct 31, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Aug 11, 2024, 9:26 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Jul 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 8, 2024, 2:00 AM EDT - 1 year ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jun 27, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

May 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 9, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024, 11:04 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

May 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

May 6, 2024, 6:10 AM EDT - 1 year ago

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

$ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma$

May 6, 2024, 6:00 AM EDT - 1 year ago

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

$ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma$

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

RadioIsotope25 Nov. 12 at 11:22 PM

0 · Reply

Rox22 Nov. 10 at 5:01 PM

0 · Reply

hechicero1131 Nov. 10 at 4:13 PM

$ADCT did anyone listen to the earnings call? Wondering when they are expected to release data readout. They have three investor conferences this month, expect to see something soon

0 · Reply

hechicero1131 Nov. 7 at 4:41 PM

$ADCT Up 5% yesterday, down 10% today - on intermediate volume. They are hiring like crazy and an earnings report on Monday. Down 10% makes no sense

0 · Reply

SamHot Nov. 6 at 10:39 PM

$ADCT

0 · Reply

Rony4AM Nov. 6 at 10:27 PM

0 · Reply

christopher18 Nov. 5 at 3:41 PM

$ADCT Earnings predictions?

0 · Reply

hechicero1131 Nov. 3 at 5:35 PM

$ADCT any insights from today’s fireside chat re. Data findings?

0 · Reply

Trhays0620 Oct. 31 at 1:31 AM

$ADCT showing a 94% loss on my position on Schwab. Anyone else have weirdness going on?

0 · Reply

scalpemfast Oct. 29 at 4:20 PM

$ADCT ,$CRWV ,$AMZN ,$ETN , all pressing up , looking strong .

0 · Reply

BEATOFtheMARKET Oct. 24 at 9:51 PM

$ACLX $ACN $ADAG $ADCT $AER 10/10 to 10/24 list results 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

Bionco Oct. 23 at 2:09 PM

$ADCT still holding!

0 · Reply

christopher18 Oct. 22 at 5:01 PM

$ADCT Will this continue to drop further into the 3s?

1 · Reply

JarvisFlow Oct. 16 at 11:23 AM

HC Wainwright & Co. updates rating for ADC Therapeutics ( $ADCT ) to Buy, target set at 8 → 7.

0 · Reply

SamHot Oct. 14 at 11:47 PM

$ADCT

0 · Reply

fort_worth_Jason Oct. 14 at 3:29 PM

$ADCT Anyone else notice this large buy today? Roughly 114k shares. This is primed and ready!

2 · Reply

fort_worth_Jason Oct. 13 at 3:30 PM

$ADCT Not sure if everyone caught these nuggets from press release. All of it is positive. They clearly know clinical trials are positive. There zero chance that you invest in commercial expansion if you know clinical trials are unfavorable. The second nugget is the increase in sales expected in Q3. This shows adoption among HCPs is occuring. Ameet is quoted as saying "we are well-positioned to acceerate our trajectory towards long-term sustainable growth." My interpretation is that they are expecting sales to go up dramatrically after newest clinical data released. I encourage y'all to do your own DD.

1 · Reply

AStrokeOfLuck Oct. 13 at 12:35 PM

$ADCT

0 · Reply

CursedTrader Oct. 13 at 12:04 PM

$ADCT Chart is not stopping 🔥

0 · Reply

DARKP00L Oct. 13 at 11:57 AM

$ADCT 07:35 on Oct. 13 2025 ADC Therapeutics Announces $60M Private Placement; Co. To Sell 11.3M Common Shares At $4.X/Share And Pre-Funded Warrants At $3.90/Share #tradeideas

0 · Reply

DonCorleone77 Oct. 13 at 11:50 AM

$ADCT ADC Therapeutics announces $60M private placement

0 · Reply

makedatbread88 Oct. 13 at 11:33 AM

$ADCT big private placement here watching

0 · Reply

Market Cap	501.70M
Revenue (ttm)	70.84M
Net Income (ttm)	-157.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-222.83%
Debt to Equity Ratio	-0.57

Volume	591,900
Avg Vol	934,812
Day's Range	N/A - N/A
Shares Out	123.88M
Stochastic %K	53%
Beta	1.98
Analysts	Strong Sell
Price Target	$8.00